Inhibikase Therapeutics Correlations

IKT Stock

USD 2.73 0.37 15.68%

The current 90-days correlation between Inhibikase Therapeutics and DiaMedica Therapeutics is 0.04 (i.e., Significant diversification). The correlation of Inhibikase Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Inhibikase Therapeutics Correlation With Market

Average diversification

The correlation between Inhibikase Therapeutics and DJI is 0.19 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and DJI in the same portfolio, assuming nothing else is changed.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.

Moving together with Inhibikase Stock

0.75	ESPR	Esperion Therapeutics	Pair Corr
0.77	EWTX	Edgewise Therapeutics	Pair Corr
0.61	BHC	Bausch Health Companies	Pair Corr
0.71	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.74	EBS	Emergent Biosolutions	Pair Corr
0.62	GANX	Gain Therapeutics	Pair Corr
0.82	GILD	Gilead Sciences	Pair Corr
0.67	MNMD	Mind Medicine	Pair Corr
0.88	CPRX	Catalyst Pharmaceuticals	Pair Corr

Moving against Inhibikase Stock

0.81	HLN	Haleon plc	Pair Corr
0.81	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.76	TAK	Takeda Pharmaceutical	Pair Corr
0.75	ZTS	Zoetis Inc	Pair Corr
0.72	ELAN	Elanco Animal Health Potential Growth	Pair Corr
0.66	RDY	Dr Reddys Laboratories	Pair Corr
0.61	LLY	Eli Lilly Sell-off Trend	Pair Corr
0.57	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.57	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.8	ANRO	Alto Neuroscience,	Pair Corr
0.61	LTRN	Lantern Pharma	Pair Corr
0.54	ANEB	Anebulo Pharmaceuticals	Pair Corr
0.51	CTLT	Catalent	Pair Corr
0.49	AMGN	Amgen Inc	Pair Corr
0.34	CVS	CVS Health Corp Aggressive Push	Pair Corr
0.33	SIGA	SIGA Technologies	Pair Corr

Related Correlations Analysis

	DMAC	MIST	MCRB	ONCY	SCPH	LIFE	GLSH	SIOX	KLDO	TPST
DMAC		0.24	-0.01	0.23	-0.37	-0.61	0.0	-0.16	-0.09	-0.2	DMAC
MIST	0.24		-0.34	-0.19	-0.57	-0.16	0.0	-0.5	0.01	-0.48	MIST
MCRB	-0.01	-0.34		-0.44	0.67	0.09	0.0	0.59	0.02	0.64	MCRB
ONCY	0.23	-0.19	-0.44		-0.28	-0.06	0.0	-0.16	-0.27	-0.3	ONCY
SCPH	-0.37	-0.57	0.67	-0.28		0.29	0.0	0.58	0.21	0.76	SCPH
LIFE	-0.61	-0.16	0.09	-0.06	0.29		0.0	0.13	-0.33	0.18	LIFE
GLSH	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	GLSH
SIOX	-0.16	-0.5	0.59	-0.16	0.58	0.13	0.0		-0.03	0.72	SIOX
KLDO	-0.09	0.01	0.02	-0.27	0.21	-0.33	0.0	-0.03		0.04	KLDO
TPST	-0.2	-0.48	0.64	-0.3	0.76	0.18	0.0	0.72	0.04		TPST
	DMAC	MIST	MCRB	ONCY	SCPH	LIFE	GLSH	SIOX	KLDO	TPST

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

TPST	+ 0.76	SCPH
TPST	+ 0.72	SIOX
SCPH	+ 0.67	MCRB
TPST	+ 0.64	MCRB
SIOX	+ 0.59	MCRB
SIOX	+ 0.58	SCPH

High negative correlations

LIFE	- 0.61	DMAC
SCPH	- 0.57	MIST
SIOX	- 0.5	MIST
TPST	- 0.48	MIST
ONCY	- 0.44	MCRB
SCPH	- 0.37	DMAC

Risk-Adjusted Indicators

There is a big difference between Inhibikase Stock performing well and Inhibikase Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Inhibikase Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
DMAC	2.47	0.46	0.15	33.37	2.00	(2.99)	5.20	(3.29)	14.14
MIST	1.85	0.22	0.13	0.26	1.57	(2.76)	7.19	(2.11)	18.66
MCRB	4.93	0.32	0.04	1.12	5.57	(5.97)	10.84	(9.78)	28.84
ONCY	3.45	0.14	(0.01)	(0.10)	3.53	(4.81)	7.83	(6.67)	36.56
SCPH	2.76	(0.63)	0.00	(0.24)	0.00	0.00	4.30	(7.09)	20.70
LIFE	2.57	0.38	0.09	2.06	2.62	(3.23)	6.45	(5.29)	28.98
GLSH	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SIOX	1.07	(0.10)	0.00	(7.75)	0.00	0.00	2.33	(2.38)	11.21
KLDO	164.82	74.08	0.00	0.90	0.00	0.00	50.00	(25.00)	4,849
TPST	3.84	(0.52)	0.00	(0.32)	0.00	0.00	6.38	(8.53)	29.55

Inhibikase Therapeutics Corporate Management

Roger Rush	Head Research	Profile
BSc FRCPC	Interim Advisor	Profile
Garth LeesRolfe	Chief Officer	Profile
Joseph CPA	Chief Officer	Profile
Surendra Singh	Manufacturing Chemistry	Profile
Dan Williams	Controller	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC